# E-DRUG: Re: Dipyrone

**URL:** https://talk.edrugplus.org/t/e-drug-re-dipyrone/3162
**Category:** e-drug
**Created:** [July 26, 1998, 7:15pm UTC](https://talk.edrugplus.org/t/e-drug-re-dipyrone/3162 "1998-07-26T19:15:04Z")
**Posts on this page:** 1
**Page:** 1

<div class="post-metadata">

### Author: ![pelias1](https://avatars.discourse-cdn.com/v4/letter/p/5f9b8f/32.png) [@pelias1](https://talk.edrugplus.org/u/pelias1)
#### Post date: [July 26, 1998, 7:15pm UTC](https://talk.edrugplus.org/t/e-drug-re-dipyrone/3162/1 "1998-07-26T19:15:04Z")

</div>

E-drug: Re: Dipyrone  
----------------------------------------------------------

The percentage of agranulocytosis produced by dipyrone, is many major [Note  
from moderator: much more than?] what the European laboratory producer  
manifests. Firstly because many of the cases of agranulocytosis in Latin  
america have not been communicated to the authorities of health, because the  
control is not effective. I have documented five cases of agranulocitosis by  
\<dipirona\> in a total of 4500 clinical histories, three of them needing  
intesive care.  
The only country that has reintroduced dipyrone is Sweden. And the efforts  
to reintroduce it in other countries have not been successful.  
In Argentina \<dipirona\> was sold without pharmacy control and used by self  
medication. To such extent that it was sold in vegetable stores, \<kioscos\>,  
butcheries and in the most unusual places.  
WHO considers since over fifteen years as irrational the use of \<dipirona\>.  
In Germany, the country which produces it, it was forbidden later that the  
president of Medical Federation of Germany might die after the use of  
\<dipirona\>. [Note from moderator: seems like the president of the medical  
association died after using dipyrone?]  
As antipyretic \<dipirona\> would be only third or forth choice.  
As analgesic it is not justified from the point of rational use of drugs as  
there are more effective analgesics which are also safer and cheaper than  
dipyrone.

Dr. Pablo Adolfo Elias.  
National University of Cuyo- Mendoza- Republic Argentina  
Telephone and Fax number 061- 212373  
\<email\> :pelias@raiz.uncu.edu.ar

[Note from moderator: I have tried to correct the English version although  
my Spanish is actually nothing to talk loud about. Hope I've got it correct.  
The Spanish version follows. KM]

Mensaje en espa�ol para el moderador:  
� El porcentaje de agaranulocitosis producido por la dipirona,es mucho mayor de  
lo que su laboratorio europeo productor manifiesta.  
En primer lugar porque muchos de los casos de agranulocitosis producidos en  
Latinoam�rica no han sido comunicados a las autoridades de salud,por las  
falencias en el sistema de farmacovigilancia.  
Yo tengo documentados cinco casos de agranulocitosis por dipirona en un total  
de 4500 historias cl�nicas,tres de ellos con internaci�n en salas de cuidados  
intensivos.  
El �nico pa�s que ha reincoroporado la dipirona es Suecia.  
Y los intentos de reincorporarla en otros pa�ses no han sido exitosos.  
En Argentina se vende la dipirona fuera del circuito m�dico y es por  
automedicaci�n.Al punto tal que dichos productos se venden en  
verduler�as,kioscos,negocios de venta de carne y en los lugares m�s ins�litos.  
La OMS considera desde hace m�s de quince a�os como irracional el uso de  
dipirona.  
En Alemania,su pa�s productor,fue prohibida luego de que el presidente de la  
Federaci�n M�dica de Alemania muriera tras el uso de dipirona.  
Solamente podr�a admitirse el uso de dipirona como antipir�tico de terecera o  
cuarta elecci�n.  
Como analg�sico no se justifica desde el punto de vista del uso racional de  
medicamentos,ya que hay anlag�sicos m�s efectivos,m�s inocuos y m�s baratos que  
la dipirona.  
Dr. Pablo Adolfo El�as  
Profesor Adjunto de Farmacoterapeutica  
Universidad Nacional de Cuyo-Mendoza-Republica Argentina  
Telefono y Fax n�mero 061-212373  
email: pelias@raiz.uncu.edu.ar

--  
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.  
Mail administrative requests to `majordomo@usa.healthnet.org'.  
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.
